Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment

Journal of Psychiatric Research

Volumn 44, Issue 8, 2010, Pages 556-560

  Paslakis, Georgios ^a   Luppa, Peter ^b   Gilles, Maria ^a   Kopf, Daniel ^a   Hamann Weber, Bettina ^a   Lederbogen, Florian ^a   Deuschle, Michael ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Depression; DHEA S; HPA axis; Mirtazapine; Remission; Venlafaxine

Indexed keywords

LORAZEPAM; MIRTAZAPINE; PRASTERONE SULFATE; VENLAFAXINE; ZOLPIDEM;

ADULT; AGE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CYCLOHEXANOLS; DEHYDROEPIANDROSTERONE SULFATE; DEPRESSION; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIANSERIN; MIDDLE AGED; RECURRENCE; SALIVA; SEX FACTORS;

EID: 77952889387     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.11.015     Document Type: Article

References (46)

1. Barrett-Connor E., von M.D., Laughlin G.A., Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. Journal of the American Geriatrics Society 1999, 47:685-691.
2. Baulieu E.E., Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. Journal of Endocrinology 1996, 150(Suppl.):S221-S239.
3. Berr C., Lafont S., Debuire B., Dartigues J.F., Baulieu E.E. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:13410-13415.
4. Bloch M., Schmidt P.J., Danaceau M.A., Adams L.F., Rubinow D.R. Dehydroepiandrosterone treatment of midlife dysthymia. Biological Psychiatry 1999, 45:1533-1541.
5. Bovenberg S.A., van Uum S.H., Hermus A.R. Dehydroepiandrosterone administration in humans: evidence based?. The Netherlands Journal of Medicine 2005, 63:300-304.
6. Coenen C.M., Thomas C.M., Borm G.F., Hollanders J.M., Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996, 53:171-176.
7. Deuschle M., Hamann B., Meichel C., Krumm B., Lederbogen F., Kniest A., et al. Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. Journal of Clinical Psychopharmacology 2003, 23:201-205.
8. Deuschle M., Luppa P., Gilles M., Hamann B., Heuser I. Antidepressant treatment and dehydroepiandrosterone sulfate: different effects of amitriptyline and paroxetine. Neuropsychobiology 2004, 50:252-256.
9. Fabian T.J., Dew M.A., Pollock B.G., Reynolds C.F., Mulsant B.H., Butters M.A., et al. Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults. Biological Psychiatry 2001, 50:767-774.
10. Gallagher P., Young A. Cortisol/DHEA ratios in depression. Neuropsychopharmacology 2002, 26:410.
11. Greco T., Graham C.A., Bancroft J., Tanner A., Doll H.A. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 μg of ethinyl estradiol. Contraception 2007, 76:8-17.
12. Grottoli S., Maccagno B., Ramunni J., Di V.L., Giordano R., Gianotti L., et al. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. Journal of Endocrinological Investigation 2002, 25:420-425.
13. Hansen C.R., Kroll J., Mackenzie T.B. Dehydroepiandrosterone and affective disorders. American Journal of Psychiatry 1982, 139:386-387.
14. Herbert J. Neurosteroids, brain damage, and mental illness. Experimental Gerontology 1998, 33:713-727.
15. Heuser I., Deuschle M., Luppa P., Schweiger U., Standhardt H., Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. Journal of Clinical Endocrinology & Metabolism 1998, 83:3130-3133.
16. Hsiao C.C. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression. Psychoneuroendocrinology 2006, 31:839-846.
17. Hsiao C.C. Positive correlation between anxiety severity and plasma levels of dehydroepiandrosterone sulfate in medication-free patients experiencing a major episode of depression. Psychiatry and Clinical Neurosciences 2006, 60:746-750.
18. Kroboth P.D., Salek F.S., Stone R.A., Bertz R.J., Kroboth F.J. Alprazolam increases dehydroepiandrosterone concentrations. Journal of Clinical Psychopharmacology 1999, 19:114-124.
19. Maayan R., Yagorowski Y., Grupper D., Weiss M., Shtaif B., Kaoud M.A., et al. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biological Psychiatry 2000, 48:693-701.
20. Majewska M.D., Demirgoren S., Spivak C.E., London E.D. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Research 1990, 526:143-146.
21. Markopoulou K., Papadopoulos A., Juruena M.F., Poon L., Pariante C.M., Cleare A.J. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology 2009, 34:19-26.
22. Maurice T., Roman F.J., Privat A. Modulation by neurosteroids of the in vivo (+)-[3H]SKF-10, 047 binding to sigma 1 receptors in the mouse forebrain. Journal of Neuroscience Research 1996, 46:734-743.
23. Michael A., Jenaway A., Paykel E.S., Herbert J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biological Psychiatry 2000, 48:989-995.
24. Morrison M.F., Ten H.T., Freeman E.W., Sammel M.D., Grisso J.A. DHEA-S levels and depressive symptoms in a cohort of African American and Caucasian women in the late reproductive years. Biological Psychiatry 2001, 50:705-711.
25. Muller M.B., Holsboer F. Mice with mutations in the HPA-system as models for symptoms of depression. Biological Psychiatry 2006, 59:1104-1115.
26. Rabkin J.G., McElhiney M.C., Rabkin R., McGrath P.J., Ferrando S.J. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. American Journal of Psychiatry 2006, 163:59-66.
27. Romeo E., Strohle A., Spalletta G., di M.F., Hermann B., Holsboer F., Pasini A., Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. American Journal of Psychiatry 1998, 155:910-913.
28. Rosenfeld R.S., Rosenberg B.J., Fukushima D.K., Hellman L. 24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfate. Journal of Clinical Endocrinology & Metabolism 1975, 40:850-855.
29. Scharnholz B, Hamann B, Lederbogen F, Schilling C, Gilles M, Onken V, et al. Antidepressive treatment with mirtazapine, but not venlafaxine lowers cortisol concentrations in saliva: a randomised-open trial. Psychiatry Research 2009, in press.
30. Schmidt P.J., Daly R.C., Bloch M., Smith M.J., Danaceau M.A., St Clair L.S., et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Archives of General Psychiatry 2005, 62:154-162.
31. Schüle C., Baghai T.C., Eser D., Schwarz M., Bondy B., Rupprecht R. Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol plasma concentrations in depressed patients. Journal of Psychiatric Research 2009, 43:538-545.
32. Schüle C., di Michele F., Baghai T., Romeo E., Bernardi G., Zwanzger P., et al. Influence of sleep deprivation on neuroactive steroids in major depression. Neuropsychopharmacology 2003, 28:577-581.
33. Scott L.V., Salahuddin F., Cooney J., Svec F., Dinan T.G. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. Journal of Affective Disorders 1999, 54:129-137.
34. T'Sjoen G.G., De V.S., Goemaere S., Van P.I., Dierick M., Van H.C., et al. Sex steroid level, androgen receptor polymorphism, and depressive symptoms in healthy elderly men. Journal of the American Geriatrics Society 2005, 53:636-642.
35. Takebayashi M., Kagaya A., Uchitomi Y., Kugaya A., Muraoka M., Yokota N., et al. Plasma dehydroepiandrosterone sulfate in unipolar major depression. Short communication. Journal of Neural Transmission 1998, 105:537-542.
36. Thomas G., Frenoy N., Legrain S., Sebag-Lanoe R., Baulieu E.E., Debuire B. Serum dehydroepiandrosterone sulfate levels as an individual marker. Journal of Clinical Endocrinology & Metabolism 1994, 79:1273-1276.
37. Tollefson G.D., Haus E., Garvey M.J., Evans M., Tuason V.B. 24 hour urinary dehydroepiandrosterone sulfate in unipolar depression treated with cognitive and/or pharmacotherapy. Annals of Clinical Psychiatry 1990, 2:39-45.
38. van Broekhoven F., Verkes R.J. Neurosteroids in depression: a review. Psychopharmacology (Berl) 2003, 165:97-110.
39. Weber B., Lewicka S., Deuschle M., Colla M., Heuser I. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 2000, 25:765-771.
40. Wolf O.T., Koster B., Kirschbaum C., Pietrowsky R., Kern W., Hellhammer D.H., et al. A single administration of dehydroepiandrosterone does not enhance memory performance in young healthy adults, but immediately reduces cortisol levels. Biological Psychiatry 1997, 42:845-848.
41. Wolkowitz O.M. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology 1994, 19:233-255.
42. Wolkowitz O.M., Reus V.I., Keebler A., Nelson N., Friedland M., Brizendine L., et al. Double-blind treatment of major depression with dehydroepiandrosterone. American Journal of Psychiatry 1999, 156:646-649.
43. Wolkowitz O.M., Reus V.I., Roberts E., Manfredi F., Chan T., Raum W.J., et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biological Psychiatry 1997, 41:311-318.
44. Yaffe K., Ettinger B., Pressman A., Seeley D., Whooley M., Schaefer C., et al. Neuropsychiatric function and dehydroepiandrosterone sulfate in elderly women: a prospective study. Biological Psychiatry 1998, 43:694-700.
45. Young A.H., Gallagher P., Porter R.J. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. American Journal of Psychiatry 2002, 159:1237-1239.
46. Zobel A.W., Nickel T., Sonntag A., Uhr M., Holsboer F., Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. Journal of Psychiatric Research 2001, 35:83-94.